Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Retatrutide Dosage Chart: 2mg to 12mg Week-by-Week Schedule
guidesComplete GLP-3 retatrutide dosage chart showing the Phase 2/3 clinical trial titration from 2mg to 12mg weekly. Includes what to expect at each dose, weight loss results by tier, side effects data, printable download, and free dosing calculator.
Retatrutide Weight Loss: Results, Timeline & What to Expect
guidesHow much weight can you lose on retatrutide? This guide covers Phase 3 and Phase 2 clinical data, a month-by-month timeline, cross-drug comparison to tirzepatide and semaglutide, body composition breakdown, and what individual factors affect your results.
Retatrutide Results: 24% Weight Loss in 48 Weeks (Trial Data)
guidesRetatrutide results from clinical trials show 24.2% weight loss at 48 weeks with the 12mg dose. Detailed breakdown of trial data, timeline of results, body composition changes, and realistic expectations.
Is Retatrutide FDA Approved? Status, Trials & Timeline (2026)
articleRetatrutide is not FDA-approved. It's currently in Phase 3 clinical trials (TRIUMPH program) with expected approval in 2027. Here's everything you need to know about its regulatory status, trial progress, and how to access it today.
Retatrutide Phase 3 Weight Loss Results: TRIUMPH Data
articleA dose-by-dose breakdown of retatrutide phase 3 weight loss results from the TRIUMPH program: TRIUMPH-1 (28.3% at 80 weeks), the 104-week extension (30.3%), TRIUMPH-4 (28.7%), safety data, and what investigational status means for access.
When Will Retatrutide Be FDA Approved? Timeline, Trials & Projections (2026)
articleA current read on the retatrutide FDA timeline. The molecule is still investigational, Lilly plans to submit a Biologics License Application (BLA) in Q1 2027, and the most defensible approval window is late 2027 to 2028. Here is what TRIUMPH Phase 3 has reported, what happens next, and how the timeline compares with tirzepatide.
Retatrutide Pen: What We Know About the Injection Device (2026)
articleRetatrutide is administered by subcutaneous injection in clinical trials, but no FDA-approved commercial pen exists as of May 2026. This explainer covers what the Phase 3 TRIUMPH trials confirm about delivery format, what grey-market pens actually are, and what a future Eli Lilly auto-injector will likely look like.
Retatrutide Clinical Trials: TRIUMPH Program Guide (2026)
articleTRIUMPH-4 showed 28.7% weight loss at 68 weeks in December 2025. Seven more retatrutide trials report in 2026. Here is the full TRIUMPH program map, how to enroll, and what the timeline means for FDA approval.